Evidence map›Paper›PMID 25673981›Full record

Trial reportInternational journal of chronic obstructive pulmonary disease2015

Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: a randomized controlled trial.

Michelle E John, John R Cockcroft, Tricia M McKeever, William R Coward, Dennis J Shale, Simon R Johnson, Jim G Thornton, Timothy W Harrison, Alan J Knox, Charlotte E Bolton

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of chronic obstructive pulmonary disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Chronic Bronchitis: Where Are We Now?Chronic obstructive pulmonary diseases (Miami, Fla.) · 2019
    Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Michelle E JohnNottingham Respiratory Research Unit, School of Medicine, University of Nottingham, Nottingham, UK.
John R CockcroftWales Heart Research Institute, Cardiff University, Cardiff, UK.
Tricia M McKeeverDivision of Epidemiology and Public Health, University of Nottingham, Nottingham, UK.
William R CowardNottingham Respiratory Research Unit, School of Medicine, University of Nottingham, Nottingham, UK.
Dennis J ShaleWales Heart Research Institute, Cardiff University, Cardiff, UK.
Simon R JohnsonNottingham Respiratory Research Unit, School of Medicine, University of Nottingham, Nottingham, UK.
Jim G ThorntonClinical Trials Unit and Department of Obstetrics and Gynaecology, School of Medicine, University of Nottingham, Nottingham, UK.
Timothy W HarrisonNottingham Respiratory Research Unit, School of Medicine, University of Nottingham, Nottingham, UK.
Alan J KnoxNottingham Respiratory Research Unit, School of Medicine, University of Nottingham, Nottingham, UK.
Charlotte E BoltonNottingham Respiratory Research Unit, School of Medicine, University of Nottingham, Nottingham, UK.
University of Nottingham · GBCardiff Metropolitan University · GBCardiff University · GB

Funding

Department of Health PB-PG-0110-21178
6 · The paper itself

Abstract

backgroundThere is excess cardiovascular mortality in patients with chronic obstructive pulmonary disease. Aortic stiffness, an independent predictor of cardiovascular risk, and systemic and airway inflammation are increased in patients with the disease. Statins modulate aortic stiffness and have anti-inflammatory properties. A proof-of-principle, double-blind, randomized trial determined if 6 weeks of simvastatin 20 mg once daily reduced aortic stiffness and systemic and airway inflammation in patients with chronic obstructive pulmonary disease.

methodsStable patients (n=70) were randomized to simvastatin (active) or placebo. Pre-treatment and post-treatment aortic stiffness, blood pressure, spirometry, and circulating and airway inflammatory mediators and lipids were measured. A predefined subgroup analysis was performed where baseline aortic pulse wave velocity (PWV) was >10 m/sec.

resultsTotal cholesterol dropped in the active group. There was no significant change in aortic PWV between the active group and the placebo group (-0.7 m/sec, P=0.24). In those with aortic stiffness >10 m/sec (n=22), aortic PWV improved in the active group compared with the placebo group (-2.8 m/sec, P=0.03). Neither systemic nor airway inflammatory markers changed.

conclusionThere was a nonsignificant improvement in aortic PWV in those taking simvastatin 20 mg compared with placebo, but in those with higher baseline aortic stiffness (a higher risk group) a significant and clinically relevant reduction in PWV was shown.

Indexed as

AgedAged, 80 and overAnti-Inflammatory AgentsBiomarkersCardiovascular AgentsCholesterolDouble-Blind MethodEnglandFemaleForced Expiratory VolumeHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation MediatorsLungMaleMiddle AgedAnti-Inflammatory AgentsBiomarkersCardiovascular AgentsCholesterolHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation MediatorsSimvastatinarterial stiffnesschronic obstructive pulmonary diseasestatins

Identifiers

PMID25673981
PMCPMC4321645
OpenAlexW1988087615

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.